The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”) conjugated to at least one pharmacological agent. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugates to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.本發明係關於包含能夠特異性結合至「含解整合素及金屬蛋白酶域之蛋白9」(「ADAM9」)、共軛至至少一種藥理學藥劑之抗體或其片段的免疫共軛物。本發明特別關於與人類ADAM9及非人類靈長類(例如，食蟹獼猴)之ADAM9具有交叉反應性的此類免疫共軛物。本發明另外關於包含輕鏈可變(VL)域及/或重鏈可變(VH)域之所有此類免疫共軛物，該輕鏈可變(VL)域及/或重鏈可變(VH)域已經人源化及/或去免疫化以便在向接受受試者投與此類免疫共軛物時展現降低的免疫原性。本發明亦關於含有此類免疫共軛物中任一者之醫藥組成物，以及涉及此類免疫共軛物中任一者在治療癌症及其他疾病及病狀中之用途的方法。
